RMC No. 103-2021 publishes updated VAT-exempt lists of medicines for hypertension, cancer, kidney diseases, and COVID-19 drugs, requiring immediate compliance for affected businesses.
Businesses and taxpayers dealing with pharmaceutical products and COVID-19 treatments must immediately review the updated VAT-exempt lists published by the FDA and DOH. This update, under RMC No. 103-2021, supplements prior guidelines and directly affects the VAT treatment of specific medicines and vaccines.
What Changed
RMC No. 103-2021 publishes the full text of letters from the Food and Drug Administration (FDA) and the Department of Health (DOH) containing the latest updates to the VAT-exempt product lists under Sections 109(1)(AA) and 109(1)(BB) of the Tax Code of 1997, as amended by R.A. Nos. 10963, 11467, and 11534. The key updates include:
1. The Corrigendum to the List of Medicines for Hypertension, Cancer, and Kidney Diseases, as issued by the FDA on August 31, 2021.
2. The list of VAT-Exempt Drugs and Vaccines prescribed and directly used for COVID-19 treatment, issued by the DOH on August 12, 2021.
These updates supplement RMC No. 81-2021, which previously consolidated VAT-exempt products.
Who is Affected
Pharmaceutical companies, hospitals, clinics, pharmacies, distributors, and importers of medicines and vaccines are directly affected. Any business involved in the sale, distribution, or importation of drugs for hypertension, cancer, kidney diseases, or COVID-19 treatment must review the updated VAT-exempt lists to ensure correct tax treatment.
Key Compliance Requirements and Deadlines
The circular takes effect immediately upon publication. Businesses must:
– Update accounting systems to reflect VAT-exemption on covered medicines and COVID-19 drugs.
– Verify product coverage against the FDA/DOH official lists, accessible at https://verification.fda.gov.ph/Home.php
.
– Ensure VAT returns reflect exemptions accurately to avoid underpayment or penalties.
Penalties for Non-Compliance
Failure to correctly apply VAT exemptions may result in administrative sanctions, including fines or assessments for VAT shortfalls. Companies could be held liable for interest and penalties on incorrectly reported transactions.
Practical Steps for Businesses
1. Immediately access the official VAT-exempt product lists via the FDA website.
2. Cross-check all current inventory and new imports against the updated list.
3. Adjust accounting records to reflect the correct VAT treatment.
4. Communicate the changes to finance, tax, and operations teams to ensure compliance.
5. Keep supporting documents, such as invoices and official correspondence, for audit purposes.
Staying compliant with RMC No. 103-2021 ensures businesses take advantage of available VAT exemptions while avoiding potential penalties. For expert guidance on implementing these updates and managing VAT-exempt products, contact Ablola, Saribong & Gueco, your trusted partner in Philippine tax compliance at MakatiLawFirm.com.